Advanced Parkinson's Disease Clinical Trial
Official title:
A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Primary Objective: To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD). Secondary Objectives: To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD. To compare the efficacy of IPX203 with IR CD-LD following multiple doses. To evaluate the safety of IPX203.
IPX203 is an investigational product containing CD-LD. IPX203-B16-01 Study Design: A randomized, open-label, rater-blinded, multicenter, 2-treatment, 2-period, multiple-dose crossover study. Approximately 30 qualified IR CD-LD-experienced advanced PD subjects will be randomized. The study duration will be approximately 8 weeks, including the screening period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02154724 -
Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease
|
N/A | |
| Completed |
NCT02549092 -
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
|
Phase 3 | |
| Completed |
NCT01960842 -
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
|
Phase 3 | |
| Completed |
NCT01723904 -
A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT01479127 -
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00660673 -
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04802733 -
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT01736176 -
A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT02082249 -
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
|
Phase 3 | |
| Completed |
NCT02611713 -
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
|
||
| Terminated |
NCT01536015 -
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
|
Phase 3 | |
| Completed |
NCT00357994 -
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
|
Phase 3 | |
| Completed |
NCT00335153 -
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
|
Phase 3 | |
| Active, not recruiting |
NCT06396494 -
An Automated Navigation System for Deep Brain Electrode Implantation
|
||
| Recruiting |
NCT06195124 -
A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease
|
Early Phase 1 | |
| Completed |
NCT00660387 -
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
|
Phase 3 |